WO1994000113A3 - Medicaments renfermant des antagonistes du recepteur de 5-ht¿4? - Google Patents

Medicaments renfermant des antagonistes du recepteur de 5-ht¿4? Download PDF

Info

Publication number
WO1994000113A3
WO1994000113A3 PCT/GB1993/001330 GB9301330W WO9400113A3 WO 1994000113 A3 WO1994000113 A3 WO 1994000113A3 GB 9301330 W GB9301330 W GB 9301330W WO 9400113 A3 WO9400113 A3 WO 9400113A3
Authority
WO
WIPO (PCT)
Prior art keywords
receptor antagonists
medicaments containing
prophylaxis
treatment
mamals
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB1993/001330
Other languages
English (en)
Other versions
WO1994000113A2 (fr
Inventor
Gareth John Sanger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929213708A external-priority patent/GB9213708D0/en
Priority claimed from GB929214399A external-priority patent/GB9214399D0/en
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Priority to AU43504/93A priority Critical patent/AU4350493A/en
Priority to JP6502163A priority patent/JPH07508276A/ja
Publication of WO1994000113A2 publication Critical patent/WO1994000113A2/fr
Publication of WO1994000113A3 publication Critical patent/WO1994000113A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/452—Piperidinium derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention se rapporte à un procédé pour le traitement et/ou la prophylaxie de troubles gastro-intestinaux associés à la motilité duodénale et/ou à des vomissements chez les mammifères, dont l'homme. Ledit procédé consiste à administrer au mammifère ayant besoin de ce type de traitement et/ou de prophylaxie une quantité efficace et/ou prophylactique d'un antagoniste du récepteur de 5-HT4.
PCT/GB1993/001330 1992-06-27 1993-06-24 Medicaments renfermant des antagonistes du recepteur de 5-ht¿4? Ceased WO1994000113A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU43504/93A AU4350493A (en) 1992-06-27 1993-06-24 Medicaments containing 5-ht4 receptor antagonists
JP6502163A JPH07508276A (ja) 1992-06-27 1993-06-24 ５−ｈｔ↓４受容体アンタゴニスト含有医薬品

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB929213708A GB9213708D0 (en) 1992-06-27 1992-06-27 Pharmaceuticals
GB9213708.2 1992-06-27
GB929214399A GB9214399D0 (en) 1992-07-07 1992-07-07 Pharmaceuticals
GB9214399.9 1992-07-07

Publications (2)

Publication Number Publication Date
WO1994000113A2 WO1994000113A2 (fr) 1994-01-06
WO1994000113A3 true WO1994000113A3 (fr) 1994-04-14

Family

ID=26301138

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1993/001330 Ceased WO1994000113A2 (fr) 1992-06-27 1993-06-24 Medicaments renfermant des antagonistes du recepteur de 5-ht¿4?

Country Status (3)

Country Link
JP (1) JPH07508276A (fr)
AU (1) AU4350493A (fr)
WO (1) WO1994000113A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5998409A (en) * 1992-03-12 1999-12-07 Smithkline Beecham Plc Condensed indole derivatives as 5HT4 -receptor antagonists
US5852014A (en) * 1992-03-12 1998-12-22 Smithkline Beecham P.L.C. Condensed indole derivatives as 5HT4 -receptor antagonists
EP0664794A1 (fr) * 1992-10-16 1995-08-02 Smithkline Beecham Plc Esters/amides n-alkylpiperidinyl-4-methyl carboxyliques des systemes de cycles condenses en tant qu'inhibiteurs de recepteurs 5-ht4
IL117438A (en) * 1995-03-16 2001-12-23 Lilly Co Eli Indazolecarboxamides, their preparation and pharmaceutical compositions containing them
US5654320A (en) * 1995-03-16 1997-08-05 Eli Lilly And Company Indazolecarboxamides
ES2208870T3 (es) * 1996-02-15 2004-06-16 Janssen Pharmaceutica N.V. Uso de antagonistas del receptor 5ht4 para resolver los efectos gastrointestinales de los inhibidores de la reabsorcion de serotonina.
US6069152A (en) * 1997-10-07 2000-05-30 Eli Lilly And Company 5-HT4 agonists and antagonists
WO2011163594A2 (fr) * 2010-06-24 2011-12-29 Alkermes, Inc. Promédicaments de composés nh-acides : dérivés esters, carbonates, carbamates et phosphonates

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0076530A2 (fr) * 1981-10-01 1983-04-13 Janssen Pharmaceutica N.V. Dérivés de la N-(3-hydroxy-4-piperidinyl)benzamide
EP0309423A2 (fr) * 1987-09-23 1989-03-29 BOEHRINGER INGELHEIM ITALIA S.p.A. Dérivés de l'acide benzimidazoline-2-oxo-1-carboxylique utiles commes antagonistes des 5-HT récepteurs
EP0501322A1 (fr) * 1991-02-25 1992-09-02 Glaxo Group Limited Esters pipéridimylmethyl substitués d'acide indole-3-carbonyligne
EP0505322A1 (fr) * 1991-03-22 1992-09-23 Sandoz Ltd. Aminoguanidines
FR2674853A1 (fr) * 1991-04-03 1992-10-09 Synthelabo Derives de piperidinylguanidine, leur preparation et leur application en therapeutique.
WO1993002677A1 (fr) * 1991-08-03 1993-02-18 Smithkline Beecham Plc Antagonistes du recepteur 5-ht4
WO1993003725A1 (fr) * 1991-08-20 1993-03-04 Smithkline Beecham Plc Antagonistes du recepteur 5-ht4
WO1993005040A1 (fr) * 1991-09-12 1993-03-18 Smithkline Beecham Plc Composes azacycliques utilises comme antagonistes du recepteur 5-ht¿4?
WO1993005038A1 (fr) * 1991-09-12 1993-03-18 Smithkline Beecham Plc Antagonistes de recepteurs 5-hydroxytriptamine 4
WO1993008187A1 (fr) * 1991-10-24 1993-04-29 Smithkline Beecham Plc Imidazopyridines et indolizines en tant qu'antagonistes de 5-ht¿4?
WO1993016072A1 (fr) * 1992-02-06 1993-08-19 Smithkline Beecham Plc Derives de benzopyrane, de benzothiopyrane et de coumarone utilises comme antagonistes du recepteur 5-ht4

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0076530A2 (fr) * 1981-10-01 1983-04-13 Janssen Pharmaceutica N.V. Dérivés de la N-(3-hydroxy-4-piperidinyl)benzamide
EP0309423A2 (fr) * 1987-09-23 1989-03-29 BOEHRINGER INGELHEIM ITALIA S.p.A. Dérivés de l'acide benzimidazoline-2-oxo-1-carboxylique utiles commes antagonistes des 5-HT récepteurs
EP0501322A1 (fr) * 1991-02-25 1992-09-02 Glaxo Group Limited Esters pipéridimylmethyl substitués d'acide indole-3-carbonyligne
EP0505322A1 (fr) * 1991-03-22 1992-09-23 Sandoz Ltd. Aminoguanidines
FR2674853A1 (fr) * 1991-04-03 1992-10-09 Synthelabo Derives de piperidinylguanidine, leur preparation et leur application en therapeutique.
WO1993002677A1 (fr) * 1991-08-03 1993-02-18 Smithkline Beecham Plc Antagonistes du recepteur 5-ht4
WO1993003725A1 (fr) * 1991-08-20 1993-03-04 Smithkline Beecham Plc Antagonistes du recepteur 5-ht4
WO1993005040A1 (fr) * 1991-09-12 1993-03-18 Smithkline Beecham Plc Composes azacycliques utilises comme antagonistes du recepteur 5-ht¿4?
WO1993005038A1 (fr) * 1991-09-12 1993-03-18 Smithkline Beecham Plc Antagonistes de recepteurs 5-hydroxytriptamine 4
WO1993008187A1 (fr) * 1991-10-24 1993-04-29 Smithkline Beecham Plc Imidazopyridines et indolizines en tant qu'antagonistes de 5-ht¿4?
WO1993016072A1 (fr) * 1992-02-06 1993-08-19 Smithkline Beecham Plc Derives de benzopyrane, de benzothiopyrane et de coumarone utilises comme antagonistes du recepteur 5-ht4

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
A.P.D.W.FORD ET AL.: "5-HYDROXYTRYPTAMINE STIMULATES CYCLIC AMP FORMATION IN THE TUNICA MUSCULARIS MUCOSAE OF THE RAT OESOPHAGUS VIA 5-HT4 RECEPTORS", EUR.J.PHARMACOL., vol. 211, no. 1, 28 January 1992 (1992-01-28), pages 117 - 120, XP023760955, DOI: doi:10.1016/0014-2999(92)90272-6 *
E.LEUNG ET AL.: "CHARACTERIZATION OF 5-HT4 RECEPTORS IN THE RAT ESOPHAGEAL MUSCULARIS MUCOSAE BY SDZ 205,557", FASEB J., vol. 6, no. 4, 1992, pages A1560 *
H.W.VAN DEN BRINK ET AL.: "R 50 595, A SELECTIVE NON-COMPETITIVE ANTAGONIST OF CISAPRIDE, BRL 24924 AND 5-HYDROXYTRYPTAMINE ON THE GUINEA-PIG ILEUM", EUR.J.PHARMACOL., vol. 181, no. 1-2, 1990, pages 119 - 125, XP025566289, DOI: doi:10.1016/0014-2999(90)90252-2 *
IBIDEM, vol. 211, no. 3, 18 February 1992 (1992-02-18), pages 430 *
M.V.WAIKAR ET AL.: "PROC.SUPPL.OCT.- DAU 6285: A PROBE FOR THE 5-HT4 RECEPTOR IN RAT OESOPHAGUS AND MONKEY BLADDER", BR.J.PHARMACOL., vol. 107, October 1992 (1992-10-01), pages 125P *
N.J.TALLEY: "REVIEW ARTICLE: 5-HYDROXYTRYPTAMINE AGONISTS AND ANTAGONISTS IN THE MODULATION OF GASTROINTESTINAL MOTILITY AND SENSATION: CLINICAL IMPLICATIONS", ALIMENT.PHARMACOL.THER., vol. 6, no. 3, June 1992 (1992-06-01), pages 273 - 289, XP000566133 *
P.BHANDARI ET AL.: "PRELIMINARY EVIDENCE FOR THE INVOLVEMENT OF THE PUTATIVE 5-HT4 RECEPTOR IN ZACOPRIDE- AND COPPER SULPHATE-INDUCED VOMITING IN THE FERRET", EUR.J.PHARMACOL., vol. 204, no. 3, 12 November 1991 (1991-11-12), pages 273 - 280 *

Also Published As

Publication number Publication date
AU4350493A (en) 1994-01-24
JPH07508276A (ja) 1995-09-14
WO1994000113A2 (fr) 1994-01-06

Similar Documents

Publication Publication Date Title
EP0715855A3 (fr) Recepteurs antagonistes NK-1 et recepteurs antagonistes 5HT3 pour le traitement des vomissements
GB2240475B (en) 5 ht-3 antagonist for the prevention or reduction of dependence
GR3029354T3 (en) 3-(5-tetrazolyl-benzyl)amino-piperidine derivatives and antagonists of tachykinins
NZ241211A (en) 16alpha,17alpha-alkylidenedioxy-11b,21-dihydroxypregan -4-ene-3,20-dione derivatives substituted by halogen in either or both of the 6alpha- or the 9alpha- position; pharmaceutical compositions, methods of preparation and treatment
WO1999017755A3 (fr) Medicaments
HU9400217D0 (en) 5-membered heterocycles, process for producing them, and pharmaceutical compositions contraining them
MY115310A (en) Substance p antagonists for the treatment of emesis
AU5194496A (en) 5-HT4 receptor antagonists
NZ228768A (en) Compositions and compounds for treating gastrointestinal motility disorders
EP0451009A3 (en) Pharmaceutical composition comprising opiate antagonists for the treatment of emotional numbness
GR3018442T3 (en) Use of an amylin antagonist for the manufacture of amedicament for the treatment of obesity and essential hypertension and related disorders.
GB9305718D0 (en) Medicaments
MXPA94006948A (es) Epibatidina y derivados de la misma como agonistasy antagonistas del receptor colinergico.
IL104706A0 (en) 3-(1h-tetrazol-5-yl)-4h-pyrido(1,2-a)pyrimidine-4-ones and process for the preparation thereof
EP1032556A4 (fr) Composes pharmaceutiquement actifs et procedes d'utilisation
AU9069191A (en) Use of angiotensin ii receptor antagonists in the prevention of restinosis
AU4163793A (en) Angiotensin II receptor antagonists for the treatment and prophylaxis of coronary heart disease
BG102667A (en) Diosgenine-containing composition
WO1991016045A3 (fr) Utilisation d'antagonistes de recepteurs 5-ht4 dans le traitement d'arythmies et d'ictus
WO1993024117A3 (fr) Medicaments pour le traitement de l'anxiete
HU9301080D0 (en) Tachiquinine receptor antagonists, isoquinolones and method for producing them
IL112024A (en) Pharmaceutical compositions comprising tetrahydropyridine derivatives substituted with oxadiazole or thiadiazole for treating gastrointestinal motility disorders
HRP940611A2 (en) Process for the preparation of solid medicinal forms with dihydropyridine type calcium antagonists
IL116826A (en) Use of 3,4-diphenyl chromans for the preparation of pharmaceutical compositions for treatment or prophylaxis of obesity
WO2000006082A3 (fr) Traitement des troubles anxieux

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AT AU BB BG BR CA CH CZ DE DK ES FI GB HU JP KP KR KZ LK LU MG MN MW NL NO NZ PL PT RO RU SD SE SK UA US VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AT AU BB BG BR CA CH CZ DE DK ES FI GB HU JP KP KR KZ LK LU MG MN MW NL NO NZ PL PT RO RU SD SE SK UA US VN

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

ENP Entry into the national phase

Ref country code: US

Ref document number: 1995 356296

Date of ref document: 19950407

Kind code of ref document: A

Format of ref document f/p: F

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA